Atea Pharmaceuticals, Inc.
General ticker "AVIR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $311.3M (TTM average)
Atea Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 27.8%.
Estimated limits based on current volatility of 2.2%: low 5.27$, high 5.50$
Factors to consider:
- Total employees count: 56 (-3.4%) as of 2024
- Top business risk factors: Regulatory and compliance, Clinical trial failure, Market competition, IP expiration, Capital shortage
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [2.41$, 5.66$]
- 2026-12-31 to 2027-12-31 estimated range: [2.44$, 5.71$]
Financial Metrics affecting the AVIR estimates:
- Positive: with PPE of -1.8 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -46.12 <= 0.30
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 65.95 > -0.65
- Negative: negative Net income
- Negative: negative Industry operating cash flow (median)
Short-term AVIR quotes
Long-term AVIR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $164.16MM | $192.95MM | $180.89MM |
| Operating Income | $-164.16MM | $-192.95MM | $-180.89MM |
| Non-Operating Income | $29.22MM | $25.49MM | $16.38MM |
| R&D Expense | $114.24MM | $144.10MM | $148.02MM |
| Income(Loss) | $-134.94MM | $-167.46MM | $-164.51MM |
| Taxes | $1.02MM | $0.93MM | $-6.16MM |
| Net Income(Loss)* | $-135.96MM | $-168.38MM | $-158.35MM |
| Stockholders Equity | $555.19MM | $438.87MM | $275.43MM |
| Assets | $594.97MM | $464.67MM | $315.22MM |
| Operating Cash Flow | $-85.39MM | $-135.50MM | $-132.03MM |
| Investing Cash Flow | $40.30MM | $56.10MM | $188.79MM |
| Financing Cash Flow | $0.26MM | $0.27MM | $-25.75MM |
| Earnings Per Share** | $-1.63 | $-2.00 | $-1.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.